Medication options in the treatment of treatment-resistant depression

References

• Heimann H. Therapy-resistant depression: symptoms and syndromes. contributions to symptomatology and syndromes. Pharmakopsychiatrie Neuropsychopharmakologie 1974; 7: 199–144
   PubMedGoogle Scholar
• Fagiolini A, Kupfer D. Is treatment-resistant depression a unique subtype of depression?. Biological Psychiatry 2003; 53: 640–648
   PubMed Web of Science ®Google Scholar
• Thase M, Rush A. Treatment-resistant depression. Psychopharmacology: the fourth generation of progress, F Bloom, D Kupfer. Raven, New York 1995; 1081–1098
   Google Scholar
• Wilhelm K, Mitchell P, Boyce P, et al. Treatment resistant depression in an Australian context I. the utility of the term and approaches to management. Australian and New Zealand Journal of Psychiatry 1994; 28: 14–22
   PubMed Web of Science ®Google Scholar
• Ellis P, Hickie I, Smith D. Summary of guidelines for the treatment of depression. Australasian Psychiatry 2003; 11: 34–38
   Google Scholar
• Mitchell P, Malhi G, Redwood B, Ball J. Summary of guidelines for the treatment of bipolar disorder. Australasian Psychiatry 2003; 11: 39–53
   Google Scholar
• Mulder R, Joyce P, Lusty S. The relationship of personality disorders to treatment outcome in depressed outpatients. Journal of Clinical Psychiatry 2003; 64: 259–264
   PubMed Web of Science ®Google Scholar
• Krishnan K. Comorbidity and depression treatment. Biological Psychiatry 2003; 53: 701–706
   PubMedGoogle Scholar
• Frankle W, Perlis R, Deckersbach T, et al. Bipolar depression: relationship between episode length and antidepressant treatment. Psychological Medicine 2002; 32: 1417–1423
   PubMed Web of Science ®Google Scholar
• Akiskal H, Bourgeois M, Angst J, Post R, Moller H, Hirschfeld R. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. Journal of Affective Disorders 2000; 59: S5–S30
   PubMed Web of Science ®Google Scholar
• Thase M, Rush A. When at first you don't succeed: sequential strategies for antidepressant nonresponders. Journal of Clinical Psychiatry 1997; 58(Suppl. 13)23–29
   PubMed Web of Science ®Google Scholar
• Tohen M, Baker R (2002) Olanzapine and olanzapine plus fluoxetine vs. placebo for bipolar depression [abstract]. Presented at the 155th annual meeting of the American Psychiatric Association. May, 18–232002. American Psychiatric Association, Philadelphia
   Google Scholar
• Shelton R, Tollefson G, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. American Journal of Psychiatry 2001; 158: 131–134
   PubMed Web of Science ®Google Scholar
• Matthews J, Bottonari K, Polania L, et al. An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses. Journal of Clinical Psychiatry 2002; 63: 1167–1170
   Google Scholar
• Keck P, McElroy S. New approaches in managing bipolar depression. Journal of Clinical Psychiatry 2003; 64(Suppl. 1)13–18
   PubMedGoogle Scholar
• Malhi G, Mitchell P, Salim S. Bipolar depression: management options. CNS Drugs 2003; 17: 9–25
   PubMed Web of Science ®Google Scholar
• Kessler R, McGonagle K, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Archives of General Psychiatry 1994; 51: 8–19
   PubMed Web of Science ®Google Scholar
• Dunner D. Acute and maintenance treatment of chronic depression. Journal of Clinical Psychiatry 2001; 62(Suppl. 6)10–16
   PubMedGoogle Scholar
• Crown W, Finkelstein S, Berndt E, et al. The impact of treatmentresistant depression on health care utilization and costs. Journal of Clinical Psychiatry 2002; 63: 963–971
   PubMed Web of Science ®Google Scholar
• Frank E, Prien R, Jarrett R, et al. Conceptualisation and rationale for consensus definitions of terms in major depression. Archives of General Psychiatry 1991; 48: 851–855
   PubMed Web of Science ®Google Scholar
• Manning J. Difficult-to-treat depressions: a primary care perspective. Journal of Clinical Psychiatry 2003; 64(Suppl. 1)24–31
   PubMedGoogle Scholar
• Nierenberg A, Wright E. Evolution of remission as the new standard in the treatment of depression. Journal of Clinical Psychiatry 1999; 60(Suppl. 22)7–11
   PubMedGoogle Scholar
• Rush J, Thase M, Dube S. Research issues in the study of difficult-to-treat depression. Biological Psychiatry 2003; 53: 743–753
   PubMed Web of Science ®Google Scholar
• Thase M, Entsuah A, Rudolph R. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. British Journal of Psychiatry 2001; 178: 234–241
   PubMed Web of Science ®Google Scholar
• Ferrier I. Treatment of major depression: Is improvement enough?. Journal of Clinical Psychiatry 1999; 60(Suppl. 6)10–14
   PubMed Web of Science ®Google Scholar
• US Department Health Human Services. Clinical Practice Guidelines Number 5: Depression in Primary Care, Vol. 2 Treatment of Major Depression. US Department Health Human Services, Rockville, MD 1993
   Google Scholar
• Nierenberg A, Amsterdam J. Treatment-resistant depression: definition and treatment approaches. Journal of Clinical Psychiatry 1990; 51(Suppl. 6)39–47
   PubMedGoogle Scholar
• Ellis P, Hickie I, Smith D. RANZCP Clinical Practice Guidelines. Summary of guidelines for the treatment of depression. Australasian Psychiatry 2003; 11: 29–33
   Google Scholar
• Beckham E, Leber W. Handbook of depression, 2nd edn. Guilford, New York 1995
   Google Scholar
• Nelson J. Overcoming treatment resistance in depression. Journal of Clinical Psychiatry 1998; 59(Suppl. 16)13–19
   PubMed Web of Science ®Google Scholar
• Dinan T. Lithium augmentation in sertraline-resistant depression: a preliminary dose–response study. Acta Psychiatrica Scandinavica 1993; 88: 300–301
   PubMedGoogle Scholar
• Katona C, Abou-Saleh M, Harrison D. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. British Journal of Psychiatry 1995; 166: 80–86
   PubMed Web of Science ®Google Scholar
• Prange A, Wilson I, Rabon A, Lipton M. Enhancement of imipramine antidepressant activity by thyroid hormone. American Journal of Psychiatry 1969; 126: 457–469
   PubMed Web of Science ®Google Scholar
• Ostroff R, Nelson J. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. Journal of Clinical Psychiatry 1999; 60: 256–259
   PubMed Web of Science ®Google Scholar
• Hirose S, Ashby C. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. Journal of Clinical Psychiatry 2002; 63: 733–736
   PubMed Web of Science ®Google Scholar
• Karki S, Masood G. Combination risperidone and SSRI–induced serotonin syndrome. Annals of Pharmacology 2003; 37: 388–391
   PubMed Web of Science ®Google Scholar
• Nelson J. Managing treatment-resistant major depression. Journal of Clinical Psychiatry 2003; 64(Suppl. 1)5–12
   PubMed Web of Science ®Google Scholar
• Thase M, Rush A, Kornstein S, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Archives of General Psychiatry 2002; 59: 233–239
   PubMed Web of Science ®Google Scholar
• Nierenberg A, Papakostas G, Petersen T, et al. Nortriptyline for treatment-resistant depression. Journal of Clinical Psychiatry 2003; 64: 35–39
   PubMedGoogle Scholar
• Barbui C, Hotopf M. Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials. British Journal of Psychiatry 2001; 178: 129–144
   PubMed Web of Science ®Google Scholar
• Poirer M, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression: double-blind randomised comparison. British Journal of Psychiatry 1999; 175: 12–16
   PubMedGoogle Scholar
• Fava M, Dunner D, Greist J, et al. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment: an open trial. Journal of Clinical Psychiatry 2001; 62: 413–420
   PubMed Web of Science ®Google Scholar
• Stahl M. Essential psychopharmacology. Cambridge University Press, Cambridge 1996
   Google Scholar
• Crismon M, Trivedi M, Pigott T, et al. The Texas Medication Algorithm Project. Report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. Journal of Clinical Psychiatry 1999; 60: 142–156
   PubMed Web of Science ®Google Scholar
• Bauer M, Whybrow P, Angst J, Versiani M, Moller H-J. World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World Journal of Biological Psychiatry 2002; 3: 5–43
   PubMedGoogle Scholar
• Steffens D, McQuoid D, Krishnan K. The Duke somatic treatment algorithm for geriatric depression [STAGED] approach. Psychopharmacological Bulletin 2002; 36: 58–68
   PubMedGoogle Scholar
• Adli M, Berghofer A, Linden M, et al. Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorder: results of a 2-year observational algorithm study. Journal of Clinical Psychiatry 2002; 63: 782–790
   PubMed Web of Science ®Google Scholar
• Hirschfeld R, Montgomery S, Aguglia E, et al. Partial and nonresponse to antidepressant therapy: current approaches and treatment options. Journal of Clinical Psychiatry 2002; 63: 826–837
   PubMed Web of Science ®Google Scholar
• Kelsey J. Treatment strategies in achieving remission in major depressive disorder. Acta Psychiatrica Scandinavica Supplement 2002; 415: 18–23
   Google Scholar
• Lam R, Wan D, Cohen N, Kennedy S. Combining antidepressants for treatment-resistant depression: a review. Journal of Clinical Psychiatry 2002; 63: 685–693
   PubMed Web of Science ®Google Scholar
• Shioe K, Kanba S. Algorithms for the pharmacotherapy of major depression. Psychiatry and Clinical Neuroscience 1999; 53: S77–S82
   Google Scholar
• Fava M. Augmentation and combination strategies in treatment-resistant depression. Journal of Clinical Psychiatry 2001; 62(Suppl. 18)4–11
   PubMedGoogle Scholar
• Szegedi A, Wetzel H, Leal M, Hartter S, Hiemke C. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. Journal of Clinical Psychiatry 1996; 57: 257–264
   PubMed Web of Science ®Google Scholar
• Debonnel G, Gobbi G, Turcotte J (2000) The alpha-2 antagonist mirtazapine combined with the SSRI paroxetine induces a greater antidepressant response: a double blind controlled study. Presented at the 39th Annual Meeting of the American College of Neuropsychopharmacology. December, 10–142000. American College of Neuropsychopharmacology, San Juan, Puerto Rico
   Google Scholar
• Carpenter L, Yasmin S, Price L. A double blind, placebo controlled study of antidepressant augmentation with mirtazapine. Biological Psychiatry 2002; 51: 183–188
   PubMed Web of Science ®Google Scholar
• Farah A. Relief of SSRI-induced sexual dysfunction with mirtazapine treatment [letter]. Journal of Clinical Psychiatry 1999; 60: 260–261
   PubMedGoogle Scholar
• Demers J, Malone M. Serotonin syndrome induced by fluvoxamine and mirtazapine. Annals of Pharmacotherapy 2001; 35: 1217–1220
   PubMed Web of Science ®Google Scholar
• Hawley C, Sivakumaran T, Ochocki M (2000) Co-administration of reboxetine and serotonin selective reuptake inhibitors in treatment-resistant patients with major depression. Presented at the 39th Annual Meeting of the American College of Neuropsychopharmacology. December, 10–142000. American College of Neuropsychopharmacology, San Juan, Puerto Rico
   Google Scholar
• Dursun S, Devarajan S (2000) The safety of reboxetine plus citalopram in treatment-resistant depression: an open, naturalistic case series. Presented at the 39th Annual Meeting of the American College of Neuropsychopharmacology. December, 10–142000. American College of Neuropsychopharmacology, San Juan, Puerto Rico
   Google Scholar
• Fleishaker J. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clinical Pharmacokinetics 2000; 39: 413–427
   PubMed Web of Science ®Google Scholar
• Nolen W, Haffmans P, Bouvy P, Duivenvoorden H. Monoamine oxidase inhibitors in resistant major depression: a double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants. Journal of Affective Disorders 1993; 28: 189–197
   PubMed Web of Science ®Google Scholar
• Thase M, Sachs G. Bipolar depression: pharmacotherapy and related therapeutic strategies. Biological Psychiatry 2000; 48: 558–572
   PubMed Web of Science ®Google Scholar
• Parker G, Roy K, Wilhelm K, Mitchell P. Assessing the comparative effectiveness of antidepressant therapies: a prospective clinical practice study. Journal of Clinical Psychiatry 2001; 62: 117–125
   PubMed Web of Science ®Google Scholar
• Post R M. Mood disorders. Comprehensive textbook of psychiatry, 6th edn., H Kaplan, B Sadock. Williams & Wilkins, Baltimore 1995; 1152–1178
   Google Scholar
• Lader M. Combined use of tricyclic antidepressants and monoamine oxidase inhibitors. Journal of Clinical Psychiatry 1983; 44: 20–24
   PubMed Web of Science ®Google Scholar
• Fawcett J, Kravitz H, Zajecka J, Schaff M. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. Journal of Clinical Psychopharmacology 1991; 11: 127–132
   PubMed Web of Science ®Google Scholar
• Lavretsky H, Kumar A. Methylphenidate augmentation of citalopram in elderly depressed patients. American Journal of Geriatric Psychiatry 2001; 9: 298–303
   PubMedGoogle Scholar
• Menza M, Kaufman K, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. Journal of Clinical Psychiatry 2000; 61: 378–381
   PubMed Web of Science ®Google Scholar
• Taylor F, Prather M. The efficiency of nefazodone augmentation for treatment-resistant depression with anxiety symptoms or anxiety disorder. Depression and Anxiety 2003; 18: 83–88
   PubMedGoogle Scholar
• Kornbluh R, Papakostas G, Petersen T, et al. A survey of prescribing preferences in the treatment of refractory depression: recent trends. Psychopharmacology Bulletin 2001; 35: 150–156
   PubMedGoogle Scholar
• Michalak E, Lam R. Breaking the myths: new treatment approaches for chronic depression. Canadian Journal of Psychiatry 2002; 47: 635–643
   PubMedGoogle Scholar
• Kennedy S, Segal Z, Cohen N, Levitan R, Gemar M, Bagby R. Lithium carbonate versus cognitive therapy as sequential combination treatment strategies in partial responders to antidepressant medication: an exploratory trial. Journal of Clinical Psychiatry 2003; 64: 439–444
   PubMedGoogle Scholar
• Perlis R, Nierenberg A, Alpert J, et al. Effects of adding cognitive therapy to fluoxetine dose increases risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder. Journal of Clinical Psychopharmacology 2002; 22: 474–480
   PubMed Web of Science ®Google Scholar